HIV/AIDS Recovery Rates in Male and Female Patients, Treated with Medicinal synthetic Aluminum-magnesium silicate

Ezeibe, Maduike C. O.; Aleeyu, Dahiru; Aneke, N. K.; Obarezi, T. N.; Ogbonna, Ijeoma J.; Kalu, Ekenma; Njoku, Njoku

doi:10.9734/bjmmr/2016/29018

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Delayed recovery of HIV/AIDS patients treated with regimen of Antivirt ® and Immunace extra-protection ® [12] may be due to the severe immune deficiency caused by HIV while the quick-cure (72 to 96 hours) of COVID-19 patients treated with same regimen may be because SARS-CoV-2 (causative agent of COVID-19) is not associated with severe immune deficiency.…”

Section: Discussionmentioning

confidence: 99%

Antivirt® {Al4(SiO4)3 + 3Mg2SiO4 → 2Al2Mg3(SiO4)3} Cures COVID-19 by Opposite Charges’ Electrostatic Attraction

Ezeibe¹,

Onyeachonam²,

Sanda³

et al. 2022

OJEpi

Self Cite

View full text Add to dashboard Cite

To cure COVID-19, we propounded mopping viruses/infected cells by opposite-charges electrostatic attraction as mechanism of treatment. RNA viruses (including COVID-19 virus) are positively charged while DNA viruses and abnormal (infected/tumor) cells are negatively charged but normal cells are neutral. Molecules of Aluminum-magnesium silicate (AMS), a WHO-approved medicine, consist of Nanoparticles that have both negatively and positively charged ends. Ultra-small size (0.96 nm thick) of the Nanoparticles, allows them access to cells in all organs. Nigeria does not have natural AMS-deposits but she has Aluminum silicate and Magnesium silicate, abundantly. These solid minerals which are WHO-approved medicines too were used to formulate an AMS-brand, named, Medicinal synthetic AMS (MSAMS, VITUMED ® , Antivirt ® ). Dextrose monohydrate (simple sugar) is incorporated in each MSAMS-formulation to convey the electrically charged Nanoparticles across mucous membranes (active-transportation) into blood for circulation to all organs. The Antivirt ® has proved effective against all viral and abnormal-cell diseases so far tested including COVID-19.

show abstract

Section: Discussionmentioning

confidence: 99%

Antivirt® {Al4(SiO4)3 + 3Mg2SiO4 → 2Al2Mg3(SiO4)3} Cures COVID-19 by Opposite Charges’ Electrostatic Attraction

Ezeibe¹,

Onyeachonam²,

Sanda³

et al. 2022

OJEpi

Self Cite

View full text Add to dashboard Cite

show abstract

“…With ten other HIV/AIDS patients earlier treated with the Antivirt ® [16], pre-treatment mean-CD4 of male patients (483.67 ± 93.01) was less than 502.43 ± 82.73 of the females though the two means were not significantly different (P = 0.88) but proliferation of CD4 T-lymphocytes (3696.67/ml) occurred in the males in Month-8 and all 3 of them became HIV-negative. The proliferation of CD4 T-lymphocytes (2548.43/ml) occurred among the females in Month-9 and 2 of them tested HIV-negative.…”

Section: Discussionmentioning

confidence: 99%

HIV-Infection Reduction-Rates in Patients, on Antiretroviral Efficacy-Trial of a Nigerian Broad-Spectrum Antiviral Medicine (Antivirt&#174;)

Ezeibe¹,

Bl²,

Onyeachonam³

et al. 2020

WJA

View full text Add to dashboard Cite

In verifying antiretroviral efficacy of a Nigerian broad spectrum antiviral medicine (Antivirt ® ), the Nigerian Institute of Medical Research certified it safe by toxicological test on laboratory animals, before commencing treatment of three HIV/AIDS patients whose viral loads varied widely (millions, hundreds of thousands and thousands). To overcome errors associated with such wide differences in subject-classes, percentages of viral load-reductions were calculated instead of comparing their viral loads. After first month of the Antivirt ® -treatment, means of ranked viral loads of the patients significantly (P ≤ 0.05) increased from 10.00 ± 7.21 to 11.30 ± 5.51 (−41.03% infection-reduction rate) instead of reducing. From second month of the trial, their viral loads started to reduce, continuously, so that their infection-reduction rates have been increasing from that −41.03%, to −38.22% in the second month; 23.98% in the third month; 31.76% in the fourth month and 64.12% after the fifth month.

show abstract

“…In one of the trials [17,18], HIV-viral loads of the patients reduced at rates of 86% in 4 weeks, 96% in 8 weeks and 99.71% in 12 weeks. In another trial [19,20] In an ongoing clinical trial, two patients who had been on antiretroviral therapy for a long time had their HIV-infections suppressed (viral loads less than 20) before the trial but their CD4 counts were still very low (207 and 115< 500). After three months of the MSAMS trial, their CD4 counts increased to 512 and 500 respectively (≥500).…”

Section: Msams: Effective Against Immune Deficiency Viral Infectionsmentioning

confidence: 99%

Electrostatic Attraction: Inhibitory-mechanism of The Medicinal Synthetic Aluminum-magnesium silicate against Electrically Charged Disease-agents (Human immune deficiency virus/Cancer-cells/Other viruses/Infected cells) and the Medicine`s Adjuvant Effects –Review

Ezeibe

Sanda

Ogbonna

et al. 2018

CJAST

Self Cite

View full text Add to dashboard Cite

Aim: To review mechanisms of actions of The medicinal synthetic Aluminum-magnesium silicate (MSAMS) as, antiviral, antiretroviral and anticancer medicine and as adjuvant. Materials and Methods: Literature-review for information on Aluminum-magnesium silicate (AMS) as a pharmaceutical binder/stabilizing agent and results of experiments on effects of electrostatic attraction, between AMS-Nanoparticles and opposite electrical charges, on diseaseagents. Findings: AMS is traditionally a pharmaceutical binder for drug-formulations. It binds medicines

show abstract

HIV/AIDS Recovery Rates in Male and Female Patients, Treated with Medicinal synthetic Aluminum-magnesium silicate

Cited by 3 publications

References 0 publications

Antivirt<sup>®</sup> {Al<sub>4</sub>(SiO<sub>4</sub>)<sub>3</sub> + 3Mg<sub>2</sub>SiO<sub>4</sub> → 2Al<sub>2</sub>Mg<sub>3</sub>(SiO<sub>4</sub>)<sub>3</sub>} Cures COVID-19 by Opposite Charges’ Electrostatic Attraction

Antivirt<sup>®</sup> {Al<sub>4</sub>(SiO<sub>4</sub>)<sub>3</sub> + 3Mg<sub>2</sub>SiO<sub>4</sub> → 2Al<sub>2</sub>Mg<sub>3</sub>(SiO<sub>4</sub>)<sub>3</sub>} Cures COVID-19 by Opposite Charges’ Electrostatic Attraction

HIV-Infection Reduction-Rates in Patients, on Antiretroviral Efficacy-Trial of a Nigerian Broad-Spectrum Antiviral Medicine (Antivirt<sup>&#174;</sup>)

Electrostatic Attraction: Inhibitory-mechanism of The Medicinal Synthetic Aluminum-magnesium silicate against Electrically Charged Disease-agents (Human immune deficiency virus/Cancer-cells/Other viruses/Infected cells) and the Medicine`s Adjuvant Effects –Review

Contact Info

Product

Resources

About

HIV/AIDS Recovery Rates in Male and Female Patients, Treated with Medicinal synthetic Aluminum-magnesium silicate

Cited by 3 publications

References 0 publications

HIV-Infection Reduction-Rates in Patients, on Antiretroviral Efficacy-Trial of a Nigerian Broad-Spectrum Antiviral Medicine (Antivirt&lt;sup&gt;&amp;#174;&lt;/sup&gt;)

Electrostatic Attraction: Inhibitory-mechanism of The Medicinal Synthetic Aluminum-magnesium silicate against Electrically Charged Disease-agents (Human immune deficiency virus/Cancer-cells/Other viruses/Infected cells) and the Medicine`s Adjuvant Effects –Review

Contact Info

Product

Resources

About

HIV-Infection Reduction-Rates in Patients, on Antiretroviral Efficacy-Trial of a Nigerian Broad-Spectrum Antiviral Medicine (Antivirt<sup>®</sup>)